|Budget Amount *help
¥18,330,000 (Direct Cost: ¥14,100,000、Indirect Cost: ¥4,230,000)
Fiscal Year 2012: ¥4,290,000 (Direct Cost: ¥3,300,000、Indirect Cost: ¥990,000)
Fiscal Year 2011: ¥4,550,000 (Direct Cost: ¥3,500,000、Indirect Cost: ¥1,050,000)
Fiscal Year 2010: ¥4,550,000 (Direct Cost: ¥3,500,000、Indirect Cost: ¥1,050,000)
Fiscal Year 2009: ¥4,940,000 (Direct Cost: ¥3,800,000、Indirect Cost: ¥1,140,000)
Transforming growth factor-β-related molecules TMEPAI, TSC22D4 (THG-1), and MafK were elucidated to initiate carcinogenic activities and promote malignant progression. Study on the molecular mechanisms how these oncogenes functioning provided the novel target molecules for cancer treatment and prevention. We established monoclonal antibodies for TMEPAI, TSC22D4, MafK, Gpnmb and so on. These antibodies will open the application of these works for clinicopathological research and cancer diagnosis.